

# A Mutation in the *SOS1* Gene Causes Hereditary Gingival Fibromatosis Type 1

Thomas C. Hart,<sup>1,2</sup> Yingze Zhang,<sup>1</sup> Michael C. Gorry,<sup>1</sup> P. Suzanne Hart,<sup>2</sup> Margaret Cooper,<sup>1</sup> Mary L. Marazita,<sup>1,2</sup> Jared M. Marks,<sup>1</sup> Jose R. Cortelli,<sup>3</sup> and Debora Pallos<sup>3</sup>

<sup>1</sup>Center For Craniofacial and Dental Genetics, Division of Oral Biology and Pathology, University of Pittsburgh School of Dental Medicine,

and <sup>2</sup>Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh; and <sup>3</sup>Department of Periodontics, School of Dentistry, University of Taubate, Taubate, Brazil

Hereditary gingival fibromatosis (HGF) is a rare, autosomal dominant form of gingival overgrowth. Affected individuals have a benign, slowly progressive, nonhemorrhagic, fibrous enlargement of the oral masticatory mucosa. Genetic loci for autosomal dominant forms of HGF have been localized to chromosome 2p21-p22 (HGF1) and chromosome 5q13-q22 (HGF2). To identify the gene responsible for HGF1, we extended genetic linkage studies to refine the chromosome 2p21-p22 candidate interval to ~2.3 Mb. Development of an integrated physical and genetic map of the interval identified 16 genes. Sequencing of these genes, in affected and unaffected HGF1 family members, identified a mutation in the *Son of sevenless-1* (*SOS1*) gene in affected individuals. In this report, we describe the genomic structure of the *SOS1* gene and present evidence that insertion of a cytosine between nucleotides 126,142 and 126,143 in codon 1083 of the *SOS1* gene is responsible for HGF1. This insertion mutation, which segregates in a dominant manner over four generations, introduces a frameshift and creates a premature stop codon, abolishing four functionally important proline-rich SH3 binding domains normally present in the carboxyl-terminal region of the *SOS1* protein. The resultant protein chimera contains the wild-type *SOS1* protein for the N-terminal amino acids 1–1083 fused to a novel 22-amino acid carboxyl terminus. Similar *SOS1* deletion constructs are functional in animal models, and a transgenic mouse construct with a comparable *SOS1* chimera produces a phenotype with skin hypertrophy. Clarification of the functional role of this *SOS1* mutant has implications for understanding other forms of gingival fibromatosis and corrective gingival-tissue management.

## Introduction


Hereditary gingival fibromatosis (HGF) is a genetically heterogeneous overgrowth condition characterized by a benign, slowly progressive, nonhemorrhagic, fibrous enlargement of maxillary and mandibular keratinized gingiva (MIM 135300). Keratinized oral gingiva constitutes a developmentally unique and functionally important component of the masticatory mucosa surrounding the teeth. Insufficient gingiva can predispose to chronic infection, pathologic recession, and oral morbidity (Smith 1997). Chronic infection of the gingival-tooth interface can result in periodontitis, an important oral pathology having potential systemic consequences (Scannapieco 1998). Too much oral gingiva is associated with improper tooth eruption resulting in malocclusion. The severity of gingival overgrowth in HGF varies among affected individuals and, in severe cases, can prevent tooth

eruption, resulting in functional and aesthetic problems (Raeste et al. 1978). Treatment by surgical resection is, in some cases, followed by a regrowth of the gingival tissues. HGF may be transmitted as a Mendelian trait, and both autosomal dominant and autosomal recessive transmission have been reported (Jorgenson and Cocker 1974). Linkage studies have localized loci for isolated, nonsyndromic autosomal dominant forms of gingival fibromatosis to chromosome 2p21-p22 (Hart et al. 1998; Xiao et al. 2000) and to chromosome 5q13-q22 (Xiao et al. 2001). In addition to nonsyndromic forms, gingival fibromatosis has been associated with a variety of syndromic manifestations. Chromosomal anomalies reported for syndromic forms of gingival fibromatosis include duplications, deletions, and/or other anomalies of chromosomes 2p13-16 (Fryns 1996; Shashi et al. 1999), 4q (MIM 252500), 8 (MIM 266270), 14q (Rivera et al. 1992), 19p (MIM 246200), 19q (MIM 248500), and Xq (Macias-Flores et al. 1984). Gingival fibromatosis is also an unwanted side effect of several pharmacological agents, including dilantin, cyclosporin, and several calcium-channel blockers (reviewed in Hassell and Hefti 1991). This drug-induced overgrowth response varies between individuals and may reflect an

Received November 29, 2001; accepted for publication January 10, 2002; electronically published February 26, 2002.

Address for correspondence and reprints: Dr. Thomas C. Hart, Center for Craniofacial and Dental Genetics, 614 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261. E-mail: [hart@sdmgenetics.pitt.edu](mailto:hart@sdmgenetics.pitt.edu)

© 2002 by The American Society of Human Genetics. All rights reserved.  
0002-9297/2002/7004-0012\$15.00



**Figure 1** Pedigree of Brazilian family with hereditary gingival fibromatosis. Affected individuals are indicated by blackened symbols. Circles denote females, and squares denote males; a slash through a symbol denotes a deceased individual. Clinically unaffected individuals are indicated by an unblackened symbol. A clinical diagnosis of unknown (or an uncertain diagnosis) is denoted by a question mark (?) within the symbol. The proband is indicated by the arrow (↗). The flattened oval symbol indicates individuals who participated in this study.

underlying, genetically determined susceptibility (Seymour et al. 1996).

Two groups have previously linked autosomal dominant HGF to an overlapping interval of chromosome 2p (Hart et al. 1998; Shashi et al. 1999; Xiao et al. 2000). As part of our ongoing efforts to identify the genetic basis for gingival fibromatosis, we developed a physical map spanning the HGF1 candidate interval, permitting us to integrate and localize 32 genetic markers and 33 genes to the interval (M.C.G. and T.C.H., unpublished data). In the present study, we describe the refinement of the HGF1 locus to a 2.3-Mb interval by extension of the pedigree and genotyping additional markers in the region. Sequence analysis of 6 known candidate genes, as well as 10 additional, previously uncharacterized genes within the refined interval, permitted us to identify a mutation, in the *Son of sevenless-1* (*SOS1*) gene, that segregated with the HGF phenotype. In this report, we describe the genomic organization of the *SOS1* gene and present evidence that a single-nucleotide-insertion mutation in codon 1083 of the *SOS1* gene is the cause of HGF1 in humans.

## Subjects and Methods

### Pedigree and Diagnosis

A large, multigenerational Brazilian family segregating HGF as a highly penetrant autosomal dominant trait was identified by proband ascertainment. Linkage studies of part of this family led to the original linkage of HGF1 to chromosome 2p21 (Hart et al. 1998). Individuals examined for the current study are shown in figure 1. All participating family members provided informed consent to protocols approved by institutional review


boards at the University of Taubate and the University of Pittsburgh. All individuals received oral and dental exams and, on the basis of the presence or absence of gingival enlargement, were classified as affected or unaffected, as described elsewhere (Hart et al. 1998). All individuals were also asked about exposure to prescription and nonprescription medications and, specifically, about exposure to medications associated with gingival overgrowth, including phenytoin, cyclosporin, and calcium-channel blockers.

### DNA-Marker Analysis

Genomic DNA was extracted from peripheral blood by standard methods using the QIAamp blood kit (Qiagen). Available family members were genotyped for STRP-type genetic markers spanning the candidate interval. In addition to 11 previously reported STRP loci, 21 novel STRP loci were developed from a 6-Mb physical map of the interval (M.C.G. and T.C.H., unpublished data). These marker loci were PCR amplified by use of fluorescence-labeled primers, permitting genotyping by conventional methods (Zhang et al. 2001). PCR products were detected by an ABI377 fluorescent sequencer and were analyzed by GENESCAN 2.1 (Applied Biosystems). Alleles were determined, and genotype data were entered into the pedigree file of the LINKAGE software package (Lathrop and Lalouel 1984).

### Parametric Linkage Calculations: LOD Scores

Sublocalization of the candidate interval for HGF1 on chromosome 2p21-p22 was achieved by means of genetic linkage studies. We calculated two-point LOD scores in the extended kindred, using the Elston-Stewart algorithm (Elston and Stewart 1971), employing the



LINKAGE program (Lathrop and Lalouel 1984) with updates to speed calculations (VITESSE and FASTLINK; see Cottingham et al. 1993; Terwilliger and Ott 1994; O'Connell and Weeks 1995). The LOD-score analyses assumed a genetic model for HGF, with autosomal dominant transmission, disease-allele frequency of 0.0001, 0%–1% phenocopy rates, and 95% penetrance.

#### *Multipoint LOD-Score Calculations*

The Markov chain–Monte Carlo (MCMC) algorithm, as implemented in the computer program SimWalk2 (Sobel and Lange 1996), was used for the multipoint LOD-score calculations.

#### *Analysis of Genes within the Candidate Interval, Identification of the *SOS1* Genomic Region, and *SOS1* Exon Sequencing*

Using bioinformatic approaches, we identified, assembled, and aligned 64 BACs, to develop a 6-Mb integrated physical and genetic map spanning the HGF1 candidate-gene region on chromosome 2p21-p22 (Zhang et al., in press; M.C.G. and T.C.H., unpublished data). By means of linkage analyses, we refined the HGF1 candidate interval to a 2.3-Mb interval. We localized six known genes to this region. Additionally, using an integrated bioinformatic and bench lab approach, we identified 10 previously uncharacterized genetic loci within the interval. All exons and intron-exon boundaries of these 16 genes were analyzed by sequence analysis. For these analyses, genomic DNA from three HGF1 affected individuals and from two unaffected (control) individuals were sequenced. Details for sequencing of all genes, including their GenBank accession numbers, will be re-

ported separately (Zhang et al., in press; M.C.G. and T.C.H., unpublished data). The genomic structure of the *SOS1* gene was determined bioinformatically and was confirmed by sequence analysis. To determine the genomic organization for the entire *SOS1* gene, all available *SOS1* mRNA and EST data were aligned to identify any possible splice variants. Exon 1 was identified from the dbEST data (NCBI dbEST Web site), since all available mRNA information began at the ATG start site in exon 2. Primers were designed with Oligo 4.02 (National Biosciences) to amplify each exon, including exon-intron boundaries for sequence analysis (table 1).

PCR amplification of the *SOS1* gene was performed as indicated in table 1, with or without Enhancer (Life Technology). Amplified DNA was purified with the QIAquick PCR Purification Kit (Qiagen) and was sequenced using the BigDyeTerminator Cycle Sequencing Kit and ABI 3700 or 310 DNA analyzer (Applied Biosystems). Sequencing was performed by use of the amplification primers and appropriate sequencing primers, as indicated in table 1. Sequence analysis was performed with Sequencher 4.1 software (GeneCodes). Genomic DNA from three affected and two unaffected family members was evaluated for the initial sequencing. Any polymorphism detected was evaluated for possible linkage to HGF1 in a larger segment of the family.

#### *RNA Verification of Wild-Type and Mutant *SOS1**

Peripheral venous blood was obtained by standard venipuncture from affected individuals, and white blood cells were isolated by Ficoll gradient separation, according to the manufacturer's instructions (Pharmacia). Gingival tissues were collected from two affected individuals

**Table 1****Primer Sets for Exonic Amplification of Human *SOS1* Gene**

EXON <sup>a</sup>	PRIMER (5'→3')		SIZE (bp)	PCR CONDITION <sup>b</sup>	GENBANK ACCESSION NUMBER
	Forward	Reverse			
01-02	CTTGCGTTTCGGAGTCCCAACTAC	AAGGGCAAAGCATTACCTCTCAG	806	C	AF441466
03	GGGTTGAGAACTCCTGACTTCTAG	TTTCCCTGTTCACCTGACATTACAA	659	B	AF441467
04	TGTGATATCCCCCTAGATAATAG	CCCTTCTCACCACATAAAATCTCTG	515	B	AF441468
05	CATTTGCTCCCTTCCCCAACTTG	GATCTTCCCCAACACATAATACAA	464	A	AF441469
06	CCAAGTCAGGGAAATTAAAGACAG	TGGAGTACATGGAGAATTCTGTGA	761	A	AF441470
07	AATACAGCCTCACTGAATTAATGT	CCTTGGCGGTATCTGTCTTCTAT	409	A	AF441471
08-09	TAGTCGTGCCCCATAATTAAATCT	TGTGCAGGGTACTCACACAATAAT	462	A	AF441472
10	ATTACTGCCTGTCACAAGATATAA	TCTAAAAGACCAGGCTTGTCACTA	501	A	AF441473
11	AGTAGCCAAGATAGAAATAATCAT	TCAAGCATCCTTTCCAGTGTACTC	1,230	A	AF441474
11 <sup>s</sup>	AGGAGCCAAACATGAGAGACACAT	AGATCCCAATAATGATGATTTACT			
12	GTGTGCAGAGGGCAAGAAATAAGT	AGGGTAATTCCAGAAAACTGACT	731	A	AF441475
13-14	AGTCCCGTAACTTTATAGTCACAT	TTACTGAGCCCCAATGACATCAAT	911	A	AF441476
13-14 <sup>s</sup>	GCGGTAAGCATTAATAAATGAAG	ACCGCAGTTGCACAGGCTGTATAT			
15	GAACAATGGGATGGACAGTCTCTA	TGCCTGGCCTTATTACTAGACACT	656	A	AF441477
16	TAAGGAAATATGCATAATTACACT	CTGCACCTCCAGCCTATGTGACAGA	418	A	AF441478
17	CTATCAGTCACCCCTGAATGTGTCT	GCTTAGGCTGGGACCTGTGAATAC	524	A	AF441479
18	GTTGTATTGGGCGTTTCTGTTAG	AAGGCACAGCAGGCACACTATGAT	586	A	AF441480
19-20	GTGACGAAGTTATTCTTAAAGTTC	TTTGGCTGGGCACTGACAAGTAAC	1,400	A	AF441481
19-20 <sup>s</sup>	GCAACTGAGATGGTACAGTGAAT	CATCTTTGATATCAGGATTTACTC			
19-20 <sup>s</sup>	ATCAGCCTTACTGTTTACGAGTAG				
21	AGGGCTTTAGCAAAATAGAATGTT	ACTTGCAGATTTTAAAGACTGATCT	776	A	AF441482
22	TGCTTGAATTGGGTTTCTACAT	AATGCTGCCAGACCCAAGAAGAGT	445	A	AF441483
23	CACTGTCTCCAGACATCTGAGAA	TTAGGTTTACAAGGCTCTGAATG	654	A	AF441484
24	CCAGGAAGTTGAGGCTACAGTGAG	TCGGTCTTTCCATATTCTAAACTG	944	D	AF441485
24 <sup>s</sup>		CGGCCAGCAATGGAATGAAGTTC			

<sup>a</sup> <sup>s</sup> denotes primers used in sequencing reactions.

<sup>b</sup> The standard PCR amplification for each exon contains: *Taq* (0.025 U/μl), 1 × PCR buffer, 25 nM each dNTP, and Mg as follows: A = 4.0 mM Mg, 95-2' + 94-30'/55-30'/72-2' 35X + 72C-10', no enhancer. B = 3.0 mM Mg, 95-2' + 94-30'/55-30'/72-2' 35X + 72C-10', no enhancer. C = 1.5 mM Mg, 95-2' + 94-30'/55-30'/72-2' 35X + 72C-10', 20% enhancer. D = 1.5 mM Mg, 95-2' + 94-30'/55-30'/72-2' 35X + 72C-10', 5% enhancer.

during routine surgery for removal of the overgrown gingival tissue. Total RNA was purified from both white blood cells and homogenized gingival tissues by use of Trizol solution (Life Technology). Approximately 1 μg of total RNA from each tissue was reverse transcribed using the Reverse Transcription System (Promega), with both oligo dT and random primers. The cDNA products were used as templates for a partial amplification of *SOS1* mRNA exon 21-24 (808 bp) and exon 19-22 (501 bp) with primer sets U3174/L3958 (5'-GGAGCCAAGG-AAAATTAGTTATAG-3'/5'-CCAACAGTGGTGGTC-CATCTCTGT-3') and U2831/L3310 (5'-ACCCTGAG-GTCCTAAAAAGACATG-3'/5'-GCTCGAATGATCG-GAATCAAATAC-3'), respectively. The PCR amplification was performed with *Taq* DNA polymerase, at an annealing temperature of 60°C. The amplified products were purified and sequenced as described above. The DNA sequences were aligned with the human *SOS1* cDNA in GenBank (accession number 306777). To further confirm the mutant allele of the *SOS1* cDNA, the amplified PCR products were subsequently cloned directly into the pGEM-Teasy vector (Promega), and

their sequences were confirmed by automated DNA sequencing.

#### Screening for the *SOS1* Exon 21 Insertion Mutation

Exon 21 of the *SOS1* gene was sequenced in 78 available family members. To determine if the C insertion in codon 1083 represented a *SOS1* polymorphism present in the general population, 208 chromosomes from clinically unaffected white and Chinese controls (104 chromosomes from each population) were also analyzed.

#### Western Blot Analysis

Total protein was extracted from gingival tissue by homogenization in lysis buffer (1% SDS, 1.0 mM sodium ortho-vanadate, 10 mM Tris, pH 7.4). Cellular lysates were electrophoresed on 6% SDS-polyacrylamide gels. Following electrophoresis, separated proteins were electroblotted onto polyvinylidene difluoride membrane. The membrane was blocked in blocking buffer (5% dry milk in phosphate-buffered saline) for 1 h at room temperature and then was incubated with 1 μg/ml primary

antibody in blocking buffer for 3 h. After rinsing, the membrane was incubated with peroxidase-conjugated secondary antibody for 1 h followed by chemiluminescence detection (NEN). Primary antibodies were rabbit anti-mouse *Sos1*, a polyclonal generated by immunization with a synthetic peptide corresponding to amino acids 1241–1260 in the C-terminus of the mouse *Sos1* and the monoclonal anti-mouse *Sos1*, directed against the N-terminus of mouse *Sos1* (BD Biosciences). The primary antibodies are known to cross-react with human *SOS1* (170 kDa). The N-terminal antibody also cross-reacts with human *SOS2* (150 kDa). The secondary antibodies were goat anti-rabbit and goat anti-mouse for the polyclonal and monoclonal primaries, respectively.

## Results

### Clinical Findings

An extended, multigenerational kindred segregating HGF was studied. Ninety-two family members were clinically examined, and blood was available from 82 family members for DNA analysis. Photographs, medical records, and family histories permitted a diagnosis in 14 deceased individuals. Thirty-eight individuals were diagnosed as affected, and 40 family members were diagnosed as unaffected (fig. 1). A diagnosis could not be determined in five individuals. Two individuals, V-2 and V-34, reported a history of taking dilantin. Because of the association with gingival overgrowth in 15%–30% of individuals taking dilantin, both individuals were given a diagnosis of unknown. A diagnosis could not be determined in three additional individuals: two were children under the age of 6 years (VI-2 and VI-4), and one was an edentulous adult (III-23). No family members reported a history of hearing loss or epilepsy, and hypertrichosis was not observed in any individuals. All family members were otherwise healthy and of normal intelligence. HGF was present in all generations, male-to-male transmission was observed, and there were approximately equal proportions of affected males and females, findings consistent with autosomal dominant transmission of the HGF phenotype. Clinical findings are consistent with a diagnosis of isolated, nonsyndromic hereditary gingival fibromatosis.


### Development of a Physical Map of the HGF1 Candidate Interval

A 6-Mb integrated physical and genetic map spanning the HGF1 candidate interval was developed (M.C.G. and T.C.H., unpublished data). This map permitted identification and localization of 32 STRP-type genetic markers and 33 genes to the interval. The integration of polymorphic genetic markers and genes in the interval permitted us to systematically refine the region segre-

gating with the HGF1 phenotype. A schematic of the region containing the smallest genetic interval segregating with the HGF1 phenotype in the Brazilian kindred studied is shown in figure 2. The refined interval is 2.3 Mb, flanked by the STRP markers 92F3-01 and D2S2238. Also indicated in figure 2 is the centromeric portion of the HGF candidate interval reported by Xiao et al. (2000), which extends in a telomeric direction from D2S2163. This refined candidate interval contained 6 known genes and 10 novel genes (table 2).

### Linkage Analyses

Results of linkage analysis for 26 STRP markers spanning the candidate interval are given in table 3 (two-point analyses) and figure 3 (multipoint analysis). On



**Figure 2** An indication of the relative positioning of STRP markers used in our analysis and genes with known functions identified in the region. All genes from *CEP3* to *SLC8A1* were sequenced in our search. *CRIMI* = cysteine-rich motor neuron 1 (locus 51232); *FEZ2* = fasciculation and elongation protein zeta 2 (locus 9637); *STRN* = striatin (locus 6801); *PRKR* = protein kinase, interferon-inducible double-stranded RNA dependent (locus 5610); *CBF2-CCAAT* = box binding transcription factor (locus 10153); *PRKCN* = protein kinase C, nu (locus 23683); *QPCT* = glutamyl-peptide cyclotransferase (locus 25797); *CEP3* = cdc42 effector protein 3 (locus 10602); *CYP1B1* = cytochrome P450, subfamily 1, polypeptide 1 (locus 1545); *ARL6ip2* = ADP-ribosylation-like factor 6 interacting protein 2 (locus 64225); *RPLP0* = ribosomal protein, acidic, P0 (locus 6175); *SFRS7* = splicing factor, arginine/serine-rich 7 (locus 6432); *SOS1* = son of sevenless (*D. melanogaster*) homolog 1 (locus 6654); *MAP4K3* = mitogen-activated protein kinase kinase kinase kinase 3 (locus 8491); and *SLC8A1* = solute carrier family 8 (sodium/calcium exchanger), member 1 (locus 6546). All loci can be accessed through LocusLink. The total region covered corresponds to 5,500,000 bases.

Table 2

Genes Identified within the Refined 2.3-Mb HGF1 Candidate Interval on 2p21-22

ID	Name	Locus ID	mRNA Accession Number	GenBank Accession Number
CEP3	Cdc42 effector protein 3	10602	NM_006449	
BLOCK 18	Unknown		AK057516	AF450120-AF450129
CYP1B1	Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1	1545	NM_000104	AF450130-AF450132
ARL6ip2	ADP-ribosylation-like factor 6 interacting protein 2	64225	NM_022374	AF449176-AF449187
BLOCK 22	Unknown			AF447702-AF447707
BLOCK 23	97% homology to ribosomal phosphoprotein, acidic, P0			AY064377
BLOCK 24	Unknown, similar to human heterogeneous nuclear ribonuclear protein L	92906	AK000155	
BLOCK 25	Unknown, 88% homology with aldose-1-epimerase from <i>Sus scrofa</i>		BC014916	AY064378-AY064385
SFRS7	Splicing factor, arginine/serine-rich 7	6432	NM_006276	AY062913-AY062919
BLOCK 26	Unknown			
BLOCK 27	Unknown			AF449188-AF449191
BLOCK 28	Unknown			AF454826-AF454826
SOS1	Son of sevenless ( <i>D. melanogaster</i> ) homolog 1	6654	NM_005633	AF441466-AF441485
MAP4K3	Mitogen-activated protein kinase kinase kinase kinase 3	8491	NM_003618	AF445385-AF445413
BLOCK 35	Unknown, SAM-dependent methyltransferase	80745		AF380566-AF380576
SLC8A1	Solute carrier family 8 (sodium/calcium exchanger), member 1	6546	NM_021097	

NOTE.—Genes were identified as indicated in the “Subjects and Methods” section. No gene without an EST and/or cDNA sequence was considered.

the basis of haplotype analysis, we were able to refine the candidate interval to ~2.3 Mb, within a genetic interval flanked by the novel marker loci 92F3-01 and D2S2238. The maximum two-point LOD score was for the marker D2S2220,  $Z_{\max} = 14.26$  at recombination fraction ( $\theta$ ) 0.00. The marker locus 173C1-01 is located within intron 7 of the *SOS1* gene ( $Z_{\max} = 12.08$  at  $\theta = 0.00$ ). The maximum multipoint location score was  $Z_{\max} = 20.18$  for D2S2220. Using the criteria of  $Z_{\max} - 1.0$  LOD, to determine the 95% CI, we placed the HGF1 locus within an ~1.6-Mb interval flanked by 92F3-01 and 288L6-01 (Conneally et al. 1985).

#### Genomic Structure of the *SOS1* Gene

The alignment of available ESTs (batch download from Unigene Hs.326392) and mRNA for *SOS1* with genomic sequences from two BACs (RP11-173C1 and R911-603F24) permitted identification and localization of 24 exons of the *SOS1* gene. One splice variant involving exon 22 was identified (Rojas et al. 1996). The genomic organization of the *SOS1* gene is shown in figure 4. The *SOS1* gene spans 136 kb and consists of 24 exons. The intronic sizes range from 30 bp to 53 kb. The open reading frame contains 4,002 nucleotides and encodes 1,333 amino acids (*hSOS1* mRNA; GenBank accession number 306777). The translation initiation codon is located at nucleotides 45–47 of exon 2, whereas the open reading frame is terminated at nucleotide 492 in exon 24.

#### Mutational Analysis

A total of 16 genes were sequenced from the 2.3-Mb candidate interval. A number of exonic and intronic polymorphisms were identified but were found not to segregate with the HGF phenotype (data not shown). A complete list of these genes is presented in table 2. Direct DNA sequencing of the *SOS1* gene identified 12 intronic SNPs spanning the *SOS1* gene (data not shown). None of these SNPs appeared to affect splice-site junctions, and none segregated with the HGF disease phenotype in this extended kindred. One exonic sequence alteration differed from the wild-type *SOS1* mRNA structure reported elsewhere. This single-nucleotide (cytosine) insertion (c.3248-3249insC) in exon 21 was identified in all individuals affected with HGF1 (fig. 5). This alteration segregated with the HGF phenotype and was not identified in any unaffected family members nor in any of the control chromosomes tested (104 from white subjects and 104 from Chinese subjects). The insertion of a single C nucleotide into codon 1083 does not change the coded amino acid (proline), but it does introduce a frameshift at codon 1084 of the *SOS1* gene. This frameshift mutation is predicted to alter the subsequent 22 amino acids (1084–1105) and to introduce a premature stop codon at codon 1106 (fig. 5). The predicted protein chimera does not contain the proline-rich Grb2 binding domains nor the five MAP kinase phosphorylation sites that are normally present in the wild-type *SOS1* protein. The presence of both the normal and mutant *SOS1* transcripts was demonstrated in RT-PCR from mRNA iso-

**Table 3****Two-Point Linkage Analysis: LOD Scores of 26 Markers Spanning 7.17 cM on Chromosome 2**

MARKER	DISTANCE <sup>a</sup> (kb)	LOD SCORE AT $\theta =$						
		.0	.01	.05	.10	.20	.30	.40
D2S2230	0	1.82	5.87	6.12	5.76	4.54	3.09	1.56
501007	140	3.19	3.14	2.92	2.64	2.02	1.35	.64
D2S2186	430	-.07	3.23	3.78	3.75	3.14	2.20	1.10
531C11-02	680	6.51	9.40	8.87	8.08	6.28	4.27	2.10
423P10-02	780	10.00	9.93	9.50	8.78	7.00	4.90	2.55
429J10-01	1,050	1.28	5.76	5.96	5.60	4.42	2.99	1.47
278G12-03	1,130	7.85	8.11	8.06	7.47	5.78	3.71	1.52
278G12-02	1,140	2.23	2.20	2.08	1.89	1.40	.85	.34
D2S2163	1,220	.67	6.53	7.30	6.99	5.54	3.64	1.60
D2S177	1,330	11.29	12.97	12.70	11.70	9.18	6.27	3.07
92F3-01	1,400	-6.78	-3.12	-.53	.39	.94	.88	.54
92F3-02	1,520	7.54	7.42	6.94	6.30	4.86	3.24	1.44
081H20-01	1,565	7.63	7.50	6.95	6.26	4.80	3.19	1.43
D2S1346	1,570	14.25	14.00	12.96	11.62	8.82	5.83	2.72
GATA190D04	1,730	6.93	6.81	6.30	5.63	4.22	2.72	1.20
D2S2220	1,800	14.26	14.02	13.04	11.75	9.01	6.05	2.92
173C1-01	2,570	12.08	11.91	11.19	10.21	8.03	5.61	2.92
288L6-01	3,210	7.27	7.18	6.78	6.21	4.90	3.40	1.75
D2S2238	3,470	11.33	11.66	11.54	10.73	8.40	5.51	2.32
509C20-01	3,580	6.96	7.06	7.10	6.81	5.67	4.08	2.13
3F16-01	3,710	5.32	10.61	10.55	9.82	7.79	5.37	2.65
D2S2272	4,190	-.16	7.85	7.83	7.21	5.54	3.60	1.56
D2S2172	5,270	-.09	7.37	7.40	6.82	5.25	3.43	1.55
D2S1356	5,670	6.47	10.15	10.56	10.02	8.07	5.56	2.71
D2S2259	6,570	-2.36	6.71	7.45	7.27	6.05	4.29	2.19
D2S119	7,170	9.43	9.61	9.57	9.02	7.31	5.17	2.67

<sup>a</sup> Marker distances relative to D2S2230, as reported from an integrated physical and genetic map of the candidate interval (M.C.G. and T.C.H., unpublished data). D2S2230 is 56.15 cM from the 2p telomere (Marshfield genetic map; Broman et al. 1998).

lated from both white blood cells and from gingival tissue of affected individuals, verifying that the mutant *SOS1* allele is transcribed.


#### Western Blot Analysis

Western blot analysis with a mouse monoclonal antibody directed against the N-terminus of the *SOS1* protein revealed the expected ~170 kDa wild-type band in all samples, as well as an ~150-kDa band that is consistent with a cross-reactive band for the smaller-sized Son of sevenless-2 protein (*SOS2*) (data not shown). An additional, smaller band of ~143 kDa, consistent with the truncated *SOS1* protein, was present in western blots for HGF gingival-tissue extracts. Western blot analysis with a polyclonal antibody directed against amino acids 1241–1260 of the mouse *Sos1* protein revealed a predominant band of 170 kDa in all samples tested, corresponding to the wild-type protein. In addition to the wild-type protein, we consistently observed a doublet band at a high molecular weight (>200 kDa) in gingival tissue from an affected individual. The stoichiometry of the two bands in the doublet differed for the two different antibodies. When the C-terminal *SOS1*-specific

antibody was used, both bands in the doublet were of equal intensity. The intensity of the lower-molecular-weight band in the doublet was significantly enhanced, with a ratio of ~1:2 (upper:lower bands) when the N-terminus-specific antibody was used. These findings are consistent with the upper-molecular-weight band containing the wild-type *SOS1* protein and the lower-molecular-weight band containing both the wild-type and the mutant *SOS1* protein.

#### Discussion

The findings of this study indicate that alteration of the carboxyl-terminal domain of the *SOS1* protein is responsible for HGF1 in an extended kindred. Genetic linkage studies localized a gene for HGF1 to a genetic interval containing the *SOS1* gene locus. Sequence analysis of genomic DNA and mRNA from individuals affected with HGF1 identified a single-cytosine insertion in exon 21 of the *SOS1* gene. On the basis of nomenclature guidelines (Antonarakis 1988), we have designated the insertion between nucleotides 126,142 and 126,143 in the genomic sequence (g.126,142-126,143insC) and between nucle-



**Figure 3** Multipoint LOD analysis of the family in the 7.5-cM interval flanking the refined HGF1 candidate interval. LOD scores are given on the X-axis, and genetic distances are indicated on the Y-axis from the telomeric end of chromosome 2p, on the left. The position of each of the 26 STRP markers tested are indicated by Roman numerals in the figure. The name corresponding to each number is indicated in the key below the figure.

otides 3248 and 3249 in the *SOS1* cDNA sequence (c.3248-3249insC). The codon for amino acid 1083 is changed from CCA to CCC. Both CCA and CCC code for proline, but the additional nucleotide produces a frameshift and an early termination of the protein (fig. 5). This mutation yields a chimeric 1,105-amino acid protein that consists of 1,083 *SOS1* N-terminal amino acids followed by 22 replaced amino acids and a premature stop codon at codon 1106 (p.K1084fsX1105).


We believe that this mutation is the cause of HGF1 on the basis of several findings. First, there is complete cosegregation between the g.126,142-126,143insC insertion and the HGF phenotype in this kindred. This nucleotide change is not present in 208 control chromosomes from unrelated healthy individuals. Second, *SOS1* is expressed in gingival tissues, the site that is clinically affected in HGF. Both the wild-type and mutant transcripts are expressed in gingival tissues of affected individuals. Western blot experiments are consistent with expression of both wild type and mutant *SOS1* protein in gingival tissue from individuals affected with HGF1. Third, the highly conserved 1,333-amino acid wild-type human *SOS1* protein is constitutively maintained in a down-regulated state. The carboxyl-terminal domain exerts negative allosteric control on the interaction of the *SOS1* catalytic domain with Ras (Corbalan-Garcia et al. 1998). The p.K1084fsX1105 mutation deletes ~20% of the *SOS1* protein, including functional domains that maintain *SOS1* in a down-regulated state. The truncated *SOS1* protein is therefore predicted to have enhanced activity. Studies in several species—including yeast, *Drosophila melanogaster*, mouse, and human—indicate that truncation of the carboxyl-terminal portion of *SOS1* is associated with a gain of function. Finally, a transgene construct with an *SOS1* carboxyl-terminal deletion induces skin-tumor development in mice. On the basis of these

findings, we hypothesize that the g.126,142-126,143insC mutation produces the truncated protein chimera p.K1084fsX1105 that causes HGF1 through a gain-of-function mechanism.

The guanine nucleotide-exchange factor *SOS1* mediates the coupling of receptor tyrosine kinases to Ras activation (Corbalan-Garcia et al. 1996). The *SOS1* protein has been studied extensively and the functional domains and crystal structure of the *SOS1* protein are known (Soisson et al. 1998; Chen et al. 1999; Wasiak et al. 2001). The human *SOS1* protein contains six well-characterized functional domains, two of which are encoded by nucleotides 3' to codon 1083 (fig. 4). These include four proline-rich SH3-binding sites and five mitogen-activated protein (MAP) kinase phosphorylation sites. Although the wild-type *SOS1* protein is constitutively maintained in a down-regulated state, human *SOS1* truncation mutants that lack either the amino terminus or the carboxyl-terminal domain display guanine nucleotide-exchange activity that is significantly greater than that in the full-length protein (Corbalan-Garcia et al. 1998).

Similar to the situation in humans (Aronheim et al. 1994), deletion of the proline-rich region in *SOS1* is also associated with enhanced *SOS1* activity in *D. melanogaster* (McCollam et al. 1995) and yeast. Additionally, a transgenic mouse model of a similar *SOS1* mutation (called "SOS-F") is associated with a dominant skin phenotype (Sibilia et al. 2000). In the SOS-F transgene construct, the C-terminal region containing the Grb2 binding site has been deleted. When the SOS-F construct is expressed in basal keratinocytes by use of a keratin 5' promoter, multiple papillomas and skin hypertrophy were observed. The skin-tumor phenotype is 100% penetrant in mice with the SOS-F mutation. These data suggest that a C-terminal truncation of the






**Figure 4** Structure of the human *SOS1* gene. *A*, Genomic organization of the *SOS1* gene. The exons and introns are represented as vertical and horizontal lines, respectively. The sizes of each intron are shown in kb. *B*, cDNA structure of the *SOS1* gene. The location of each exon is shown with the nucleotide numbers (bp). Since we did not determine the exact termini of the *SOS1* cDNA, the N- and C-terminals are marked with dashed lines. The translation start and stop codon are labeled as ATG and TGA, respectively. The asterisk (\*) marks the single-nucleotide insertion between nucleotides 3248 and 3249. The 5' and 3' UTRs are shaded. *C*, Structure of the wild-type *SOS1* protein. The location of each domain is marked by the amino acid numbers, with the initiation Met as amino acid 1. RhoGEF = guanine nucleotide-exchange factor for the Rho-Rac/cdc42-like GTPases region. PH = Pleckstrin homology domain. RasGEFN = guanine nucleotide-exchange factor for Ras-like GTPases; N-terminal motif. RasGEF = guanine nucleotide-exchange factor for Ras-like GTPases. PRGB = proline-rich Grbs-binding domain. In the PRGB domain, the location of the four proline-rich SH3 binding sites and the five phosphorylated serine residues are indicated by P and S, respectively. Codon 1083 (proline), where the single-nucleotide insertion occurs in HGF1, is indicated as P<sub>1083</sub>. *D*, Structure of the mutant *SOS1* protein identified in patients with HGF. The 22-amino acid missense addition at the C-terminal end are marked with a black-diamond pattern.

*SOS1* protein is functional and could produce the gingival overgrowth clinically observed in human HGF1 with the *SOS1* mutation. Why the HGF phenotype appears localized to the gingiva is unknown. The keratinized masticatory mucosa is recognized to be developmentally unique (Gao and Mackenzie 1992), and different tissue-specific signaling pathways in this unique tissue may be responsible for the limited tissue distribution of the gingival fibromatosis phenotype. Although the site-specific localization of this phenotype is remarkable, the gingiva is also the only site affected in drug-induced and most syndromic forms of gingival fibromatosis.

Interpretation of western blot analyses of extracts from human gingiva with *SOS1* antibodies are complicated by the cross-reactivity of *SOS1* antibodies with the related *SOS2* protein (~150 kDa), and by the presence of *SOS1* as part of high-molecular-weight complexes (>200 kDa) in gingiva. Nonetheless, protein extracts from HGF-affected tissues were consistent with the presence of a truncated *SOS1* protein band (143 kDa). However, it appears that the majority of the trun-

cated (mutant) protein is associated in the high molecular-weight complex, thus supporting a functional role for the truncated protein. Although the components of the high molecular-weight species are not known, *SOS1* has been reported to form a complex with Grb2 (Li et al. 1993), src-type tyrosine kinase (Park et al. 1998), and phospholipase C- $\gamma$ 1 (Kim et al. 2000). A complex is also observed between Grb2/*SOS1* and the epidermal growth factor (EGF) receptor after EGF stimulation (Hu and Bowtell 1996). The ability of mutant *SOS1* protein to form complexes may lead to constitutive activation of its downstream targets.

The genetic basis for gingival fibromatosis in humans is heterogeneous (Witkop 1971; Gorlin 1990; Hart et al. 2000). Loci for autosomal dominant HGF have been localized to an overlapping interval on chromosome 2p21-p22 (Hart et al. 1998; Shashi et al. 1999; Xiao et al. 2000), suggesting that a gene locus within the 3.8-cM overlap may be causal for HGF1. Evaluation of linkage data presented here, by use of a recently developed 6-Mb integrated physical and genetic map of the HGF1 candidate interval, indicates that the two chro-



**Figure 5** Mutation in *SOS1*, revealed by sequencing of exon 21. The ATG translation initiation codon, encoded by exon 2, is taken as nucleotide 1. A, Sequences of (a) wild type, (b) genomic DNA from an affected individual, and (c) cloned affected cDNA allele amplification from an affected individual. The insertion of a C nucleotide in genomic sequences between nucleotides 126,142 and 126,143 (b) and in cDNA between nucleotides 3248 and 3249 (c) are shown by arrows. p.R1084fsX1105 indicates that this mutation produces a frameshift with Arginine1084 as the first amino acid affected and that the new reading frame is open for 22 amino acids. B, Amino acid sequences of codons 1083-1106 of the wild type and predicted amino acid sequences of the mutant *SOS1* proteins. The premature termination codon is indicated by "Stop."

mosome 2p21-p22 HGF linkage intervals are distinct (fig. 2). The *SOS1* gene locus is ~1.3 Mb centromeric to the linkage interval reported in Chinese families affected with HGF (Xiao et al 2000). Whether there are two distinct HGF loci in close proximity on chromosome 2p21-p22 is unknown. Mutational analysis of the *SOS1* gene in families demonstrating linkage to chromosome 2p21-p22 may clarify genetic heterogeneity of HGF.

The *SOS1* mutation in individuals with HGF described in this report represents the first genetic mutation identified for isolated HGF. Whether the increase in gingival tissue observed in the HGF1 phenotype is a result of increased cellular proliferation, increased cell survival, and/or inhibition of cellular differentiation is not known. Identification of the specific genetic basis in HGF1 should help to elucidate the pathogenic mechanism by which gingival overgrowth occurs. Understanding the mechanism by which gingival fibromatosis develops may have implications for understanding how certain drugs induce gingival overgrowth and may have applications for the nonsurgical treatment of gingival insufficiency.

**Acknowledgments**

This investigation was supported in part by United States Public Health Service research grant DE10990 from the Na-

tional Institute of Dental and Craniofacial Research, National Institutes of Health.

**Electronic-Database Information**

Accession numbers and URLs for data in this article are as follows:

- LocusLink, <http://www.ncbi.nlm.nih.gov/LocusLink/> (for loci shown in fig. 2)
- Marshfield Center for Medical Genetics, <http://research.marshfieldclinic.org/genetics/> (for position of marker D2S2230)
- NCBI dbEST database, <http://www.ncbi.nlm.nih.gov/blast/Blast.cgi>
- Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for fibrous enlargement of maxillary and mandibular keratinized gingiva [MIM 135300], anomalies of chromosome 4q [MIM 252500], anomalies of chromosome 8 [MIM 266270], anomalies of chromosome 19p [MIM 246200], and chromosome 19q [MIM 248500])

**References**

Antonarakis SE (1998) Recommendations for a nomenclature system for human gene mutations. Hum Mutat 11:1-3  
Aronheim A, Engelberg D, Li N, Al Alawi N, Schlessinger J, Karin M (1994) Membrane targeting of the nucleotide

- exchange factor Sos is sufficient for activating the Ras signaling pathway. *Cell* 78:949–961
- Broman KW, Murray JC, Sheffield VC, White RL, Weber JL (1998) Comprehensive human genetic maps: individual and sex-specific variation in recombination. *Am J Hum Genet* 63:861–869
- Chen JM, Friedman FK, Hyde MJ, Monaco R, Pincus MR (1999) Molecular dynamics analysis of the structures of ras-guanine nucleotide exchange protein (SOS) bound to wild-type and oncogenic ras-p21: identification of effector domains of SOS. *J Protein Chem* 18:867–874
- Conneally PM, Edwards JH, Kidd KK, Lalouel JM, Morton NE, Ott J, White R (1985) Report of the committee on methods of linkage analysis and reporting. *Cytogenet Cell Genet* 40:356–359
- Corbalan-Garcia S, Margarit SM, Galron D, Yang SS, Bar-Sagi D (1998) Regulation of SOS activity by intramolecular interactions. *Mol Cell Biol* 18:880–886
- Corbalan-Garcia S, Yang SS, Degenhardt KR, Bar-Sagi D (1996) Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. *Mol Cell Biol* 16:5674–5682
- Cottingham RW Jr, Idury RM, Schäffer AA (1993) Faster sequential genetic linkage computations. *Am J Hum Genet* 53:252–263
- Elston RC, Stewart J (1971) A general model for the genetic analysis of pedigree data. *Hum Hered* 21:523–542
- Fryns JP (1996) Gingival fibromatosis and partial duplication of the short arm of chromosome 2 (dup(2)(p13→p21)). *Ann Genet* 39:54–55
- Gao Z, Mackenzie IC (1992) Patterns of phenotypic expression of human junctional, gingival and reduced enamel epithelia in vivo and in vitro. *Epithelial Cell Biology* 1:156–167
- Gorlin RJ, Cohen MM, Levi LS (1990) Syndromes of the head and neck. In: Gorlin RJ, Cohen MM Jr, Levin LS (eds) *Syndromes of the head and neck*. Oxford University Press, New York, pp 847–857
- Hart TC, Pallos D, Bowden DW, Bolyard J, Pettenati MJ, Cortelli JR (1998) Genetic linkage of hereditary gingival fibromatosis to chromosome 2p21. *Am J Hum Genet* 62:876–883
- Hart TC, Pallos D, Bozzo L, Almeida OP, Marazita ML, O'Connell JR, Cortelli JR (2000) Evidence of genetic heterogeneity for hereditary gingival fibromatosis. *J Dent Res* 79:1758–1764
- Hassell TM, Hefti AF (1991) Drug-induced gingival overgrowth: old problem, new problem. *Crit Rev Oral Biol Med* 2:103–137
- Hu Y, Bowtell DD (1996) Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation. *Oncogene* 12:1865–1872
- Jorgenson RJ, Cocker ME (1974) Variation in the inheritance and expression of gingival fibromatosis. *J Periodontol* 45:472–477
- Kim MJ, Chang JS, Park SK, Hwang JI, Ryu SH, Suh PG (2000) Direct interaction of SOS1 Ras exchange protein with the SH3 domain of phospholipase C-gamma1. *Biochemistry* 39:8674–8682
- Lathrop GM, Lalouel JM (1984) Easy calculations of lod scores and genetic risks on small computers. *Am J Hum Genet* 36:460–465
- Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Bar-Sagi D, Margolis B, Schlessinger J (1993) Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. *Nature* 363:85–88
- Macias-Flores MA, Garcia-Cruz D, Rivera H, Escobar-Lujan M, Melendrez-Vega A, Rivas-Campos D, Rodriguez-Collazo F, Moreno-Arellano I, Cantu JM (1984) A new form of hypertrichosis inherited as an X-linked dominant trait. *Hum Genet* 66:66–70
- McCollam LL, Bonfini CA, Karlovich BR, Conway LM, Kozma Banerjee U, Czech MP (1995) Functional roles for the pleckstrin and Dbl homology regions in the Ras exchange factor Son-of sevenless. *J Biol Chem* 270:15954–15957
- O'Connell JR, Weeks DE (1995) The VITESSE algorithm for rapid exact multilocus linkage analysis via genotype set-recoding and fuzzy inheritance. *Nat Genet* 11:402–408
- Park C, Choi Y, Yun Y (1998) Son of sevenless binds to the SH3 domain of src-type tyrosine kinase. *Mol Cells* 8:518–523
- Raeste AM, Collan Y, Kilpinen E (1978) Hereditary fibrous hyperplasia of the gingiva with varying penetrance and expressivity. *Scand J Dent Res* 86:357–365
- Rivera HM, Ramirez-Duenas L, Figueroa LE, Gonzalez-Montes RM, Vasquez AI (1992) Opposite imbalances of distal 14q in two unrelated patients. *Ann Genet* 35:97–100
- Rojas JM, Coque JJ, Guerrer C, Aroca P, deMora JF, de la Cruz X, Lorenzi MV, Esteban LM, Santos E (1996) A 15 amino acid stretch close to the Grb2-binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity. *Oncogene* 12:2291–2300
- Scannapieco FA (1998) Position paper of The American Academy of Periodontology: periodontal disease as a potential risk factor for systemic diseases. *J Periodontol* 69:841–850
- Seymour RA, Thomason JM, Ellis JS (1996) The pathogenesis of drug-induced gingival overgrowth. *J Clin Periodontol* 23:165–175
- Shashi V, Pallos D, Pettenati MJ, Cortelli JR, Fryns JP, Kapherr C, Hart TC (1999) Genetic heterogeneity of gingival fibromatosis on chromosome 2p. *J Med Genet* 36:683–686
- Sibilia MA, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J, Wagner EF (2000) The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. *Cell* 102:211–220
- Smith RG (1997) Gingival recession: reappraisal of an enigmatic condition and a new index for monitoring. *J Clin Periodontol* 24:201–205
- Sobel E, Lange K (1996) Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. *Am J Hum Genet* 58:1323–1337
- Soisson SM, Nimnual AS, Uy M, Bar-Sagi D, Kuriyan J (1998) Crystal structure of the Dbl and pleckstrin homology domains from the human Son of sevenless protein. *Cell* 95:259–268
- Terwilliger JD, Ott J (1994) *Handbook of human genetic linkage*. Johns Hopkins University Press, Baltimore
- Wasiak S, Quinn C, Ritter B, de Heuvel E, Baranes D, Plomann M, McPherson PS (2001) The Ras/Rac guanine nucleotide

- exchange factor mammalian Son-of-sevenless interacts with PACSIN 1/syndapin I, a regulator of endocytosis and the actin cytoskeleton. *J Biol Chem* 276:26622-26628
- Witkop CJ Jr (1971) Heterogeneity in gingival fibromatosis. *Birth Defects Orig Artic Ser* 7:210-221
- Xiao S, Bu L, Zhu L, Zheng G, Yang M, Qian M, Hu L, Liu J, Zhao G, Kong X (2001) A new locus for hereditary gingival fibromatosis (GINGF2) maps to 5q13-q22. *Genomics* 74:180-185
- Xiao S, Wang X, Qu B, Yang M, Liu G, Bu L, Wang Y, Zhu L, Lei H, Hu L, Zhang X, Liu J, Zhao G, Kong X (2000) Refinement of the locus for autosomal dominant hereditary gingival fibromatosis (GINGF) to a 3.8-cM region on 2p21. *Genomics* 68:247-252
- Zhang Y, Gorrry MC, Hart PS, Pettenati MJ, Marks MJ, Lu X, Hart TC. Localization, genomic organization, and alternative transcription of a novel human SAM-dependent methyltransferase gene on chromosome 2p21-p22. *Cytogenet Genome Res* (in press)
- Zhang Y, Lundgren T, Renvert S, Tatakis DN, Firatli E, Uygur C, Hart PS, Gorrry MC, Marks JJ, Hart TC (2001) Evidence of a founder effect for four cathepsin C gene mutations in Papillon-Lefevre syndrome patients. *J Med Genet* 38: 96-101